Assessing Penumbra (PEN) Valuation As Trial Hopes Contrast With A High Earnings Multiple

Recent performance snapshot

Penumbra (PEN) has drawn investor attention after recent trading, with the stock last closing at US$324.65. Short term moves have been mixed, with a small 1 day gain alongside a slight 7 day decline.

See our latest analysis for Penumbra.

Looking past the latest move, Penumbra’s recent share price return has been softer, with a 90 day decline of 4.8%. However, the year to date share price return of 4.92% sits alongside a 12.44% total shareholder return over the last 12 months, suggesting longer term holders have still seen gains even as near term momentum has cooled.

If you are comparing Penumbra with other opportunities in the sector, this could be a good moment to widen your search using the 35 healthcare AI stocks

With Penumbra reporting solid recent shareholder returns alongside revenue and net income growth, yet trading below the average analyst price target and an intrinsic value estimate, should you view current levels as a buying opportunity, or as a sign that markets already reflect expectations for future growth in the current price?

Most Popular Narrative: 11.2% Undervalued

With Penumbra last closing at $324.65 versus a narrative fair value of $365.79, the most followed view sees the current price sitting at a discount built on detailed earnings and margin assumptions.

The soon to be released STORM PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism; a positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Read the complete narrative.

Want to see what kind of revenue climb and margin profile sit behind that fair value estimate? The narrative leans on compounded growth, rising profitability and a rich earnings multiple. The full set of assumptions may surprise you.

Result: Fair Value of $365.79 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative can unravel if competition pressures pricing, or if key trials like STORM PE or Thunderbolt fail to support current clinical and earnings expectations.

Find out about the key risks to this Penumbra narrative.

Another View: High Multiple Signals Valuation Tension

While the narrative fair value suggests Penumbra is 11.2% undervalued, the current P/E of 74.6x tells a different story. It sits well above the US Medical Equipment industry at 23.9x, the peer average at 26.1x, and even the fair ratio estimate of 28.9x. This points to meaningful valuation risk if sentiment cools.

The gap between today’s rich P/E and the lower fair ratio is what you are really focusing on, because a move closer to 28.9x could hurt returns even if the business keeps growing. Which side of that trade off feels more realistic to you right now: the upbeat narrative, or the stretched multiple?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and valuation tension here feels familiar, now is the moment to look at the numbers yourself and move quickly while sentiment is still forming. To see what investors are currently excited about, take a closer look at the 2 key rewards

Looking for more investment ideas?

If you stop at one stock, you risk missing opportunities that fit your goals even better. Keep scanning the market while momentum is still building.

• Target potential bargains by running your own filter for companies trading below what their quality suggests using the 51 high quality undervalued stocks
• Prioritise resilience and financial strength by focusing on businesses with robust balance sheets through the solid balance sheet and fundamentals stocks screener (44 results)
• Spot early opportunities before they become crowded trades by checking out the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com